AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 71 min read$AGMB

Epstein David R purchased $86K of AGMB

Epstein David R purchased 10,000 shares of AgomAb Therapeutics NV (AGMB) at an average of $8.64 ($8.57–$8.70) across 2 trades over 2026-10-05 to 2026-10-06.

Original reporting
SEC EDGAR · Epstein David R
Published Oct 7, 2026, 12:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 1:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AGMB
Bullish
high confidence
Mentioned
$AGMB
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AGMBBullishLow
01

Why it matters

The director's purchase could be interpreted as a vote of confidence, potentially prompting short-term buying interest.

02

Market read

A modest insider purchase with limited market impact; primarily of interest to AGMB shareholders and biotech-focused traders.

03

What to watch

The transaction size is small; market may have already priced in insider activity.

Relevance 4/10Novelty 4/10Timing: post-market filing on 2026-10-07

Background

Form 4 filings provide the first public disclosure of insider transactions, offering transparency into insider sentiment.

Company-level read

Ticker impact

$AGMBBullishHigh confidence
Context

Director Epstein David R purchased 10,000 shares of AGMB for $86,350, disclosed via a Form 4 filing.

Expected impact

modest upward pressure as the market prices in the director's confidence

Evidence & confidence

A direct purchase by a director is a material insider signal, though the transaction size is modest relative to market cap.

Market effects

Sector

Minor positive signal for the biotech sector, but limited impact.

Regional

No significant regional effect.

Global

Low relevance to global markets.

Counterpoint

What could challenge this read

The purchase may be routine portfolio rebalancing, not a strong endorsement.

Key entities

  • Company
    AgomAb Therapeutics NV

    Biotech firm developing antibody therapeutics, ticker AGMB.

  • Person
    Epstein David R

    Director of AGMB who made the disclosed purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AGMB insider trading history →

Related articles

OCT 14
$AGMBMedAI 8/10

Agomab Doses First Patient In Phase 2b Ontunisertib Trial For Crohn's Disease

AgomAb Therapeutics (AGMB) dosed the first patient in a Phase 2b trial of Ontunisertib for Crohn's disease. The trial aims to enroll 320 adults with symptomatic fibrostenosing Crohn's disease across multiple countries. Ontunisertib has FDA Fast Track Designation and showed positive results in an earlier Phase 2a trial. The study's primary endpoint is endoscopic passability of ileal strictures at Week 24.

rttnews.com2 min
OCT 13
$AGMBMedAI 8/10

Agomab Doses First Patient in Global Phase 2b NOV-ERA Trial for Fibrostenosing Crohn’s Disease

Agomab Therapeutics (AGMB) dosed the first patient in its global Phase 2b NOV-ERA trial for fibrostenosing Crohn’s disease. The study will enroll 320 adults to evaluate ontunisertib over 52 weeks, with a primary endpoint at Week 24. The trial follows positive Phase 2a data and triggers a €7 million milestone payment. AGMB has a Buy rating and $28 price target from analysts.

tipranks.com1 min
OCT 8
LowAI 8/10

Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation

Agomab Therapeutics will present Phase 2a STENOVA trial data on ontunisertib for Fibrostenosing Crohn’s disease at UEG Week 2026. The open-label extension results support the initiation of the global NOV-ERA Phase 2b study. Agomab will also host a symposium on fibro-inflammation in IBD. Ontunisertib is an investigational drug designed to inhibit ALK5/TGF-β in the GI tract.

globenewswire.com2 min
OCT 2
$AGMBMedAI 8/10

H.C. Wainwright reiterates Agomab stock rating on trial data

H.C. Wainwright reiterated a Buy rating and $35 price target on Agomab Therapeutics (AGMB) after positive Phase 2a STENOVA trial data. The stock is near its 52-week low, down 18% in a week. Analysts' price targets range from $28 to $60. Agomab has no debt and holds more cash, providing financial flexibility. Piper Sandler and B. Riley also initiated coverage with positive ratings and targets of $60 and $34, respectively.

investing.com2 min
OCT 1
$AGMBMedAI 8/10

Why is Agomab Therapeutics stock sliding today?

Agomab Therapeutics (AGMB) shares fell 6.1% despite positive 60-week trial data for ontunisertib, showing sustained disease control in Crohn’s patients. The decline followed a pre-market gain and a downgrade to 'Sell' by Wall Street Zen. The stock's 52-week range is $8.75 to $17.82, with a current price of $10.43, below the consensus target.

investing.com2 min
OCT 1
$AGMBHighAI 8/10

Agomab stock jumps on positive trial data

Agomab Therapeutics (NASDAQ:AGMB) shares rose 6.3% premarket after positive trial data for ontunisertib in Crohn's disease. The STENOVA extension study showed favorable safety, low event rates, and sustained disease control. 97% of patients were in remission at Week 48. The company plans a Phase 2b study. Ontunisertib has FDA Fast Track Designation.

investing.com2 min